| Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: 3rd Annual H.C. Wainwright BioConnect Investor Conference on Tuesday, May 20th 2025 RBC Capital Markets Global Healthcare Conference Company presentation Wednes. |
businesswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals price target raised by $4 at Raymond James, here's why |
29 May |
https://thefly.com |
2025-05-13 12:08:21 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-05-09 22:00:00 |
Czytaj oryginał (ang.) |
| Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL |
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $mirm #easl2025--Volixibat Data from Mirum's VANTAGE PBC Study Showcased at EASL. |
businesswire.com |
2025-05-09 12:30:00 |
Czytaj oryginał (ang.) |
| Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised |
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. |
zacks.com |
2025-05-08 17:16:05 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals, Inc. (MIRM) Q1 2025 Earnings Call Transcript |
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Andrew McKibben - SVP, Strategic Finance and IR Chris Peetz - CEO Peter Radovich - President and COO Eric Bjerkholt - CFO Conference Call Participants Gavin Clark-Gartner - Evercore Jessica Fye - JPMorgan Selena Zhang - Morgan Stanley Ryan McElroy - Leerink Partners David Lebowitz - Citi Ryan Deschner - Raymond James Luke Herrmann - Baird Catherine Novack - Citizens Operator Hello and welcome to Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results. My name is Carla, and I'll be coordinating your call today. |
seekingalpha.com |
2025-05-08 01:17:17 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates |
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2025-05-07 22:30:46 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update. |
businesswire.com |
2025-05-07 20:01:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals: A Respectable Liver, Rare Disease Franchise With Pipeline Opportunities |
Mirum Pharmaceuticals boasts a strong portfolio with LIVMARLI, Ctexli, and Cholbam, as well as two promising pipeline candidates --volixibat and MRM-3379-- both of which carry billion-dollar potential. The company is expected to be cash flow positive by the end of FY 2025, with significant revenue growth projected for 2025 and 2026. Upcoming data presentations and earnings could drive the stock higher, with analysts' price targets ranging from $54 to $74 per share. |
seekingalpha.com |
2025-05-04 22:45:02 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025. |
businesswire.com |
2025-04-30 12:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #algs--Mirum Pharmaceuticals to Present Data at Upcoming Medical Congresses. |
businesswire.com |
2025-04-28 12:30:00 |
Czytaj oryginał (ang.) |
| Mirum's LIVMARLI Now FDA Approved in Tablet Formulation |
FOSTER CITY, Calif.--(BUSINESS WIRE)---- $MIRM #alagillesyndrome--Mirum's LIVMARLI Now FDA Approved in Tablet Formulation. |
businesswire.com |
2025-04-14 12:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-04-10 23:00:00 |
Czytaj oryginał (ang.) |
| LIVMARLI Now Approved in Japan for ALGS and PFIC |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--LIVMARLI Now Approved in Japan for ALGS and PFIC. |
businesswire.com |
2025-03-27 10:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call |
Mirum Pharmaceuticals, Inc. stock has risen nearly 25% since my "Sell" rating in October, prompting a re-evaluation of the company's performance and prospects. Mirum markets three drugs: LIVMARLI, Cholbam, and Chenodal, with LIVMARLI showing significant growth in treating cholestatic pruritus in ALGS and PFIC. Mirum's 2024 net product sales reached $336.4m, an 88% year-on-year increase, driven by LIVMARLI and the newly acquired bile acid medicines. |
seekingalpha.com |
2025-03-24 19:17:28 |
Czytaj oryginał (ang.) |
| Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe |
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock. |
zacks.com |
2025-03-21 15:40:26 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-03-10 22:00:00 |
Czytaj oryginał (ang.) |
| MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates |
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same. |
zacks.com |
2025-02-27 13:25:27 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript |
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Chris Peetz - Chief Executive Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI Jessica Fye - JPMorgan David Lebowitz - Citi Rohit Bhasin - Morgan Stanley Ryan Deschner - Raymond James Jonathan Wolleben - Citizens JMP Operator Hello, and welcome to Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update. My name is Elliot, and I'll be your coordinator today. |
seekingalpha.com |
2025-02-27 09:10:46 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates |
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.66 per share a year ago. |
zacks.com |
2025-02-26 20:16:08 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2024 and provided a business update. “2024 was another year of significant growth and accomplishments for Mirum and in 2025 we expect this momentum to continue,” said Chris Peetz, chief executive officer of Mirum. “We continue to expand the reach of our three commercial medicines within our patient communities and look forward to another year of s. |
businesswire.com |
2025-02-26 18:01:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals (MIRM): Here's What You Should Know |
The mean of analysts' price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2025-02-26 12:56:14 |
Czytaj oryginał (ang.) |
| Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX) |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #ctx--Mirum's CTEXLI™ (chenodiol) Tablets Receives FDA Approval for Treatment of Cerebrotendinous Xanthomatosis (CTX). |
businesswire.com |
2025-02-24 10:30:00 |
Czytaj oryginał (ang.) |
| US FDA approves Mirum Pharma's genetic disorder drug |
The U.S. Food and Drug Administration said on Friday it has approved Mirum Pharmaceuticals' drug to treat a type of rare disorder, which affects the body's ability to metabolize fats known as cholesterol. |
reuters.com |
2025-02-21 14:01:16 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call on February 26, 2025. |
businesswire.com |
2025-02-19 18:04:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals (MIRM) is on the Move, Here's Why the Trend Could be Sustainable |
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2025-02-17 11:51:12 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-02-10 21:00:00 |
Czytaj oryginał (ang.) |
| Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why |
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
zacks.com |
2025-01-30 11:50:46 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock? |
Mirum Pharmaceuticals (MIRM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-01-24 15:01:13 |
Czytaj oryginał (ang.) |
| MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results |
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals. |
zacks.com |
2025-01-16 15:11:08 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why |
If you are looking for stocks that are well positioned to maintain their recent uptrend, Mirum Pharmaceuticals (MIRM) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen. |
zacks.com |
2025-01-14 11:51:14 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates. |
businesswire.com |
2025-01-13 10:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2025-01-10 20:30:00 |
Czytaj oryginał (ang.) |
| Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) |
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3) |
seekingalpha.com |
2025-01-08 13:05:43 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference. |
businesswire.com |
2025-01-06 18:04:00 |
Czytaj oryginał (ang.) |
| Mirum Pharma: Buy At Dips For Volixibat Potential |
Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 years away from approval, but supported in the interim by the other approved drugs. Financially, Mirum has a market cap of $2bn, a cash balance of $294mn, and a cash runway of over 12-15 quarters. |
seekingalpha.com |
2024-12-25 12:00:00 |
Czytaj oryginał (ang.) |
| Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report? |
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:28 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2024-12-10 20:00:00 |
Czytaj oryginał (ang.) |
| Mirum Shares Surge More Than 90% in 6 Months: Here's Why |
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise. |
zacks.com |
2024-11-29 13:01:12 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript |
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI. Jessica Fye - JP Morgan Dae Gon Ha - Stifel Brian Skorney - Baird David Lebowitz - Citi Thomas Yip - H.C. |
seekingalpha.com |
2024-11-12 15:51:32 |
Czytaj oryginał (ang.) |
| Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised |
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. |
zacks.com |
2024-11-12 14:45:36 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates |
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago. |
zacks.com |
2024-11-12 12:15:29 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2024-11-08 20:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences. |
businesswire.com |
2024-11-07 18:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024 |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024. |
businesswire.com |
2024-11-04 18:30:00 |
Czytaj oryginał (ang.) |
| Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know |
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-31 13:05:44 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting . |
businesswire.com |
2024-10-31 10:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2024-10-10 23:30:00 |
Czytaj oryginał (ang.) |
| Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis |
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pbc--Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis. |
businesswire.com |
2024-10-10 12:30:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2024-09-11 00:45:00 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue? |
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-06 16:37:51 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference Company presentation - Wednesday, September 4th starting at 8:30 a.m. ET H.C. Wainwright 26th Annual Glo. |
businesswire.com |
2024-08-28 20:01:00 |
Czytaj oryginał (ang.) |
| Mirum (MIRM) Banks on Livmarli, Overdependence a Concern |
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. |
zacks.com |
2024-08-19 16:11:23 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript |
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Jon Wolleben - Citizens JMP Steven Seedhouse - Raymond James David Lebowitz - Citi Mike Ulz - Morgan Stanley Jessica Fye - JPMorgan Gavin Clark-Gartner - Evercore ISI Mani Foroohar - Leerink Partners Dae Gon Ha - Stifel Operator Good afternoon, everyone, and welcome to the Mirum Pharmaceuticals reports Second Quarter 2024 Financial Results and provides Business Update. My name is Carla, and I will be coordinating your call today. |
seekingalpha.com |
2024-08-10 01:10:02 |
Czytaj oryginał (ang.) |
| Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). |
businesswire.com |
2024-08-09 23:00:00 |
Czytaj oryginał (ang.) |